In Vitro and In Vivo Activities of the Novel Azole Antifungal Agent R126638

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 2, 2004, Pages 388-391

  Odds, F ^a   Ausma, J ^b   Van Gerven, F ^c   Woestenborghs, F ^c   Meerpoel, L ^c   Heeres, J ^d   Vanden Bossche, H ^c   Borgers, M ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Barrier Therapeutics NV   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 (4 (4 ((4 (2,4 DIFLUOROPHENYL) 4 (1H 1,2,4 TRIAZOL 1 YLMETHYL) 1,3 DIOXOLAN 2 YL)METHOXY)PHENYL)PIPERAZIN 1 YL)PHENYL) 3 (1 METHYLETHYL) 2 IMIDAZOLIDINONE; 1 [4 [4 [4 [[4 (2,4 DIFLUOROPHENYL) 4 (1H 1,2,4 TRIAZOL 1 YLMETHYL) 1,3 DIOXOLAN 2 YL]METHOXY]PHENYL]PIPERAZIN 1 YL]PHENYL] 3 (1 METHYLETHYL) 2 IMIDAZOLIDINONE; 1-(4-(4-(4-((4-(2,4-DIFLUOROPHENYL)-4-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-2-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)PHENYL)-3-(1-METHYLETHYL)-2-IMIDAZOLIDINONE; ANTIFUNGAL AGENT; AZOLINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATOMYCOSIS; DERMATOPHYTE; DOSE RESPONSE; DRUG EFFECT; DRUG STRUCTURE; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; MALASSEZIA; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MICROSPORA; MICROSPORUM CANIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN; SYNTHESIS; TINEA; TRICHOPHYTON; TRICHOPHYTON MENTAGROPHYTES;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; DERMATOMYCOSES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; IMIDAZOLES; ITRACONAZOLE; KETOCONAZOLE; MICE; MICROBIAL SENSITIVITY TESTS; MICROSPORIDIA; SKIN; TINEA; TRIAZOLES; TRICHOPHYTON;

EID: 0942268851     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.2.388-391.2004     Document Type: Article

References (11)

1. 1 mice. Immunology 73:186-190.
2. Finney, D. J. 1971. Statistical methods in biological assay, 3rd ed. Charles Griffen & Company, Cambridge, United Kingdom.
3. Guého, E., G. Midgley, and J. Guillot. 1996. The genus Malassezia with description of four new species. Antonie Leeuwenhoek 69:337-355.
4. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 2nd ed., vol. 17, no. 9. NCCLS, Wayne, Pa.
5. Odds, F. C. 1992. Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents. Antimicrob. Agents Chemother. 36:1727-1737.
6. Odds, F. C., A. J. P. Brown, and N. A. R. Gow. 2003. Antifungal agents mechanisms of action. Trends Microbiol. 11:272-279.
7. Odds, F. C., L. Vranckx, and F. Woestenborghs. 1995. Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob. Agents Chemother. 39:2051-2060.
8. Styrt, B., and B. Sugarman. 1991. Estrogens and infection. Rev. Infect. Dis. 13:1139-1150.
9. Sugita, T., M. Takashima, T. Shinoda, H. Suto, T. Unno, R. Tsuboi, H. Ogawa, and A. Nishikawa. 2002. New yeast species. Malassezia dermatis, isolated from patients with atopic dermatitis. J. Clin. Microbiol. 40:1363-1367.
10. Vanden Bossche, H., L. Koymans, and H. Moereels. 1995. P450 inhibitors of use in medical treatment: focus on mechanisms of action. Pharmacol. Ther. 67:79-100.
11. Van Gerven, F., and F. C. Odds. 1995. The anti-Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents-bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Mycoses 38:389-393.